Economic evaluation of a childhood obesity prevention programme for children: Results from the WAVES cluster randomised controlled trial conducted in schools.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2019
Historique:
received: 07 11 2018
accepted: 21 06 2019
entrez: 11 7 2019
pubmed: 11 7 2019
medline: 27 2 2020
Statut: epublish

Résumé

Childhood obesity is a serious public health challenge and schools have been identified as an ideal place to implement prevention interventions. The aim of this study was to measure the cost-effectiveness of a multi-faceted school-based obesity prevention intervention targeting children aged 6-7 years when compared to 'usual activities'. A cluster randomised controlled trial in 54 schools across the West Midlands (UK) was conducted. The 12-month intervention aimed to increase physical activity by 30 minutes per day and encourage healthy eating. Costs were captured from a public sector perspective and utility-based health related outcomes measured using the CHU-9D. Multiple imputation using chained equations was used to address missing data. The cost effectiveness was measured at 30 months from baseline using a hierarchical net-benefit regression framework, that controlled for clustering and prespecified covariates. Any uncertainty in the results was characterised using cost-effectiveness acceptability curves. At 30 months, the total adjusted incremental mean cost of the intervention was £155 (95% confidence interval [CI]: £139, £171), and the incremental mean QALYs gained was 0.006 (95% CI: -0.024, 0.036), per child. The incremental cost-effectiveness at 30 months was £26,815 per QALY and using a standard willingness to pay threshold of £30,000 per QALY, there was a 52% chance that the intervention was cost-effective. The cost-effectiveness of the school-based WAVES intervention was subject to substantial uncertainty. We therefore recommend more research to explore obesity prevention within schools as part of a wider systems approach to obesity prevention. This paper uses data collected by the WAVES trial: Controlled trials ISRCTN97000586 (registered May 2010).

Sections du résumé

BACKGROUND
Childhood obesity is a serious public health challenge and schools have been identified as an ideal place to implement prevention interventions. The aim of this study was to measure the cost-effectiveness of a multi-faceted school-based obesity prevention intervention targeting children aged 6-7 years when compared to 'usual activities'.
METHODS
A cluster randomised controlled trial in 54 schools across the West Midlands (UK) was conducted. The 12-month intervention aimed to increase physical activity by 30 minutes per day and encourage healthy eating. Costs were captured from a public sector perspective and utility-based health related outcomes measured using the CHU-9D. Multiple imputation using chained equations was used to address missing data. The cost effectiveness was measured at 30 months from baseline using a hierarchical net-benefit regression framework, that controlled for clustering and prespecified covariates. Any uncertainty in the results was characterised using cost-effectiveness acceptability curves.
RESULTS
At 30 months, the total adjusted incremental mean cost of the intervention was £155 (95% confidence interval [CI]: £139, £171), and the incremental mean QALYs gained was 0.006 (95% CI: -0.024, 0.036), per child. The incremental cost-effectiveness at 30 months was £26,815 per QALY and using a standard willingness to pay threshold of £30,000 per QALY, there was a 52% chance that the intervention was cost-effective.
CONCLUSIONS
The cost-effectiveness of the school-based WAVES intervention was subject to substantial uncertainty. We therefore recommend more research to explore obesity prevention within schools as part of a wider systems approach to obesity prevention.
TRIAL REGISTRATION
This paper uses data collected by the WAVES trial: Controlled trials ISRCTN97000586 (registered May 2010).

Identifiants

pubmed: 31291330
doi: 10.1371/journal.pone.0219500
pii: PONE-D-18-32067
pmc: PMC6619792
doi:

Banques de données

ISRCTN
['ISRCTN97000586']

Types de publication

Comparative Study Journal Article Randomized Controlled Trial Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0219500

Subventions

Organisme : Department of Health
ID : 06/85/11
Pays : United Kingdom
Organisme : Department of Health
ID : SRF-2017-10-002
Pays : United Kingdom

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

Int J Behav Nutr Phys Act. 2016 Aug 22;13:94
pubmed: 27549382
Med Decis Making. 2013 Nov;33(8):1051-63
pubmed: 23913915
J Sch Health. 2008 Dec;78(12):619-24
pubmed: 19000237
Obesity (Silver Spring). 2010 Jan;18(1):131-6
pubmed: 19444231
BMC Public Health. 2015 May 13;15:488
pubmed: 25968599
Gac Sanit. 2011 May-Jun;25(3):198-204
pubmed: 21324563
Qual Life Res. 2009 Oct;18(8):1105-13
pubmed: 19693703
Eur J Health Econ. 2013 Apr;14(2):185-95
pubmed: 21986721
Arch Dis Child. 1995 Jul;73(1):25-9
pubmed: 7639544
Qual Life Res. 2018 Jun;27(6):1455-1462
pubmed: 29404925
J Occup Environ Med. 2014 Apr;56(4):441-5
pubmed: 24662952
Occup Ther Health Care. 2013 Apr;27(2):99-112
pubmed: 23855569
Prev Med. 1993 Mar;22(2):167-77
pubmed: 8483856
Med Decis Making. 2012 Mar-Apr;32(2):350-61
pubmed: 22016450
Lancet. 2017 Dec 16;390(10113):2627-2642
pubmed: 29029897
BMC Health Serv Res. 2006 Jun 06;6:68
pubmed: 16756680
BMJ. 2008 Sep 29;337:a1655
pubmed: 18824488
BMC Public Health. 2010 Apr 09;10:184
pubmed: 20380692
JAMA. 2016 Sep 13;316(10):1093-103
pubmed: 27623463
Trials. 2013 Dec 05;14:421
pubmed: 24308301
BMJ. 2018 Feb 7;360:k211
pubmed: 29437667
Health Econ. 2005 May;14(5):487-96
pubmed: 15497198
Health Technol Assess. 2018 Feb;22(8):1-608
pubmed: 29436364
Gesundheitswesen. 2013 Nov;75(11):742-6
pubmed: 24081572
BMJ. 2009 Jun 29;338:b2393
pubmed: 19564179
Lancet Child Adolesc Health. 2018 Jan;2(1):35-45
pubmed: 29302609
Pharmacoeconomics. 2012 Aug 1;30(8):729-47
pubmed: 22788262
PLoS One. 2013 Oct 18;8(10):e77971
pubmed: 24205050
Cost Eff Resour Alloc. 2007 Sep 06;5:12
pubmed: 17822546

Auteurs

Alastair Canaway (A)

Institute of Applied Health Research, University of Birmingham, Birmingham, United Kingdom.

Emma Frew (E)

Institute of Applied Health Research, University of Birmingham, Birmingham, United Kingdom.

Emma Lancashire (E)

Institute of Applied Health Research, University of Birmingham, Birmingham, United Kingdom.

Miranda Pallan (M)

Institute of Applied Health Research, University of Birmingham, Birmingham, United Kingdom.

Karla Hemming (K)

Institute of Applied Health Research, University of Birmingham, Birmingham, United Kingdom.

Peymane Adab (P)

Institute of Applied Health Research, University of Birmingham, Birmingham, United Kingdom.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH